A pilot study was conducted to determine effects of an empowerment intervention on antiretroviral therapy (ART) adherence among Thai youth living with HIV/AIDS. It compared two groups of 23 young persons (15-24 years) who receive ART from AIDS clinics at two community hospitals. One hospital's patients served as the experimental group, and the other as a control group. The experimental groups attended five sessions that empowered them to take control of their own health. The control group received the standard of care. The data were analyzed using descriptive statistics and Chi-square statistics. Before the empowerment, no one from the experimental group or the control group had ART adherence ≥ 95%. After the intervention, the 82.6% of the experimental group had ≥ 95% adherence compared to the control group, which had 21.7% adherence (p < .0001). The empowerment intervention resulted in a significant increase in ART adherence among Thai youth.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375063PMC
http://dx.doi.org/10.1080/08964289.2014.911717DOI Listing

Publication Analysis

Top Keywords

control group
16
empowerment intervention
12
adherence thai
12
thai youth
12
art adherence
12
experimental group
12
intervention antiretroviral
8
group control
8
≥ 95%
8
group
7

Similar Publications

The presence of N-nitrosamine impurities in pharmaceutical products is well known. In 2019, it resulted in drug recall by the Food and Drug Administration (FDA). Soon, several groups identified the presence of many N-nitrosamines (NAs) in various Active Pharmaceutical Ingredients (APIs) and drug formulations worldwide.

View Article and Find Full Text PDF

Effects of Ab501 (certolizumab mice equivalent) in arthritis induced bone loss.

ARP Rheumatol

January 2024

Instituto de Medicina Molecular-João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Portugal.

Introduction - Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease, which causes local and systemic bone damage. The main goal of this work was to analyze, how treatment intervention with Ab501 (certolizumab mice equivalent) prevents the disturbances on bone structure and mechanics induced by arthritis. Methods - Thirty DBA/1 collagen-induced arthritis (CIA) mice were randomly housed in experimental groups, as follows: arthritic untreated (N=9), preventive intervention (N=10) and treatment intervention (N=11).

View Article and Find Full Text PDF

Background: This study aimed to evaluate the effects of administering flunixin meglumine (FM) and meloxicam (M) on specific days post-mating on progesterone (P4), total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), pregnancy-specific protein B (PSPB), pregnancy-associated glycoprotein (PAG) concentrations and fertility parameters in Awassi sheep.

Methods: Seventy-five Awassi sheep were divided into three groups of 25: control, M and FM. On days 9 and 10 post-mating, the control group received saline, the M group received 0.

View Article and Find Full Text PDF

Breast cancer (BC) commonly expresses estrogen receptors (ERs); hence, endocrine therapy targeting ERs is considered an effective treatment. Tamoxifen (TAM) resistance is an essential clinical complication leading to cancer progression and metastasis. This study investigated MicroRNAs (miRNAs) potentially implicated in drug resistance (miR-182-3p, miR-382-3p) or sensitivity (miR-93, miR- 142- 3p).

View Article and Find Full Text PDF

Purpose: Reperfusion of the ischaemic heart is essential to limit myocardial infarction. However, reperfusion can cause cardiomyocyte hypercontracture. Recently, cardiac myosin-targeted inhibitors (CMIs), such as Mavacamten (MYK-461) and Aficamten (CK-274), have been developed to treat patients with cardiac hypercontractility.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!